Actinium Pharmaceuticals, Inc. (ATNM) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Actinium Pharmaceuticals, Inc. (ATNM) closed at USD 0.98 on 2026-10-14, a change of -34.1 % over the past year, with a market capitalization of USD 33.33M.

Actinium Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Actinium Pharmaceuticals, Inc. key figures

Previous close

USD 0.98 (2026-10-14)

1-year change

-34.1 %

Market cap

USD 33.33M

Enterprise value

USD -1.8M

P/E ratio (trailing)

2.94

P/E ratio (forward)

-2.02

EPS (trailing)

0.36

EPS (forward)

-0.53

PEG ratio

n/a

Price to book

1.10

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.22

Employees

27

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Actinium Pharmaceuticals, Inc. and compare it with other stocks.